Efficacy of infliximab on the acute attack of uveitis

Saudi Medical Journal

Volumn 31, Issue 1, 2010, Pages 82-85

  Alokaily, Fahdah ^a   Alsaleh, Sulaiman ^a   Al Balawi, Maryseon ^a   Al Rashidi, Seham ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; INFLIXIMAB; PREDNISOLONE; STEROID; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MALE; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; FEMALE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 77949343136     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Al-Dalaan AN, Al-Balaa SR, El-Ramahi K, Al-Kawi Z, Bohlega S, Bahabri S, et al. Behçet's disease in Saudi Arabia. J Rheumatol 1994; 21: 658-661.
2. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 1284-1291.
3. Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997; 24: 128-132.
4. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006; 33: 231-237.
5. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990; 322: 281-285.
6. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 1998; 134: 1010-1016.
7. Ozyazgan Y, Yurdakul S, Yazici H, Tüzün B, Isçimen A, Tüzün Y, et al. Low dose cyclosporine A versus pulsed cyclosphosphmide in behcet's syndrome, a single masked trial Br J Ophth 1992; 76: 241-243.
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-296.
9. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89: 533-536.
10. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-2484.
11. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46: 1161-1164.
12. Lopez-Gonzalez R, Loza E, Jover JA, Benitez Del Castillo JM, Mendez R, Hernandez-Garcia C, et al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol 2009; 38: 58-62.